H e m a t o lo g y E d u c a t io n - European Hematology Association

Wingard JR, Young J-AH, Boeckh MJ. Guidelines for
Preventing Infectious Complications among Hematopoietic
Cell Transplantation Recipients: A Global Perspective.
Biology of Blood and Marrow Transplantation. 2009;15:1143-
238.
5. Boeckh M, Ljungman P. How we treat cytomegalovirus in
hematopoietic cell transplant recipients. Blood. 2009;113(23):
5711-9.
6. Casper C, Englund J, Boeckh M. How I treat influenza in
patients with hematologic malignancies. Blood. 2010;115(7):
1331-42.
7. Shah JN, Chemaly RF. Management of RSV infections in adult
recipients of hematopoietic stem cell transplantation. Blood.
Mar 10;117(10):2755-63.
8. Lindemans CA, Leen AM, Boelens JJ. How I treat adenovirus
in hematopoietic stem cell transplant recipients. Blood.
2010;116(25):5476-85.
9. Heslop HE. How I treat EBV lymphoproliferation. Blood.
2009 Nov 5;114(19):4002-8.
10. Boeckh M. The challenge of respiratory virus infections in
hematopoietic cell transplant recipients. Br J Haematol. 2008;
143:455-67.
11. Yusuf U, Hale GA, Carr J, Gu Z, Benaim E, Woodard P, et al.
Cidofovir for the treatment of adenoviral infection in pediatric
hematopoietic stem cell transplant patients.
Transplantation. 2006;81(10):1398-404.
12. Nagafuji K, Aoki K, Henzan H, Kato K, Miyamoto T, Eto T, et
al. Cidofovir for treating adenoviral hemorrhagic cystitis in
hematopoietic stem cell transplant recipients. Bone Marrow
Transplant. 2004;34(10):909-14.
13. Paolino K, Sande J, Perez E, Loechelt B, Jantausch B, Painter
W, et al. Eradication of disseminated adenovirus infection in
a pediatric hematopoietic stem cell transplantation recipient
using the novel antiviral agent CMX001. J Clin Virol. Feb
2011;50(2):167-70.
14. Naesens L, Lenaerts L, Andrei G, Snoeck R, Van Beers D, Holy
A, et al. Antiadenovirus activities of several classes of nucleoside
and nucleotide analogues. Antimicrob Agents
Chemother. 2005 Mar;49(3):1010-6.
15. Abdallah A, Rowland KE, Schepetiuk SK, To LB, Bardy P. An
outbreak of respiratory syncytial virus infection in a bone
marrow transplant unit: effect on engraftment and outcome
of pneumonia without specific antiviral treatment. Bone
Marrow Transplant. 2003 Jul;32(2):195-203.
16. Boeckh M, Englund J, Li Y, Miller C, Cross A, Fernandez H, et
al. Randomized controlled multicenter trial of aerosolized ribavirin
for respiratory syncytial virus upper respiratory tract
infection in hematopoietic cell transplant recipients. Clin
Infect Dis. 2007 Jan 15;44(2):245-9.
17. Khanna N, Widmer AF, Decker M, Steffen I, Halter J, Heim D,
et al. Respiratory syncytial virus infection in patients with
hematological diseases: single-center study and review of the
literature. Clin Infect Dis. 2008 Feb 1;46(3):402-12.
18. Chemaly RF, Ghosh S, Bodey GP, Rohatgi N, Safdar A,
Keating MJ, et al. Respiratory viral infections in adults with
hematologic malignancies and human stem cell transplantation
recipients: a retrospective study at a major cancer center.
Medicine (Baltimore). 2006 Sep;85(5):278-87.
19. Lewinsohn DM, Bowden RA, Mattson D, Crawford SW.
Phase I study of intravenous ribavirin treatment of respiratory
syncytial virus pneumonia after marrow transplantation.
Antimicrob Agents Chemother. 1996;40(11):2555-7.
20. Sparrelid E, Ljungman P, Ekelof-Andstrom E, Aschan J,
Ringden O, Winiarski J, et al. Ribavirin therapy in bone marrow
transplant recipients with viral respiratory tract infections.
Bone marrow transplantation. 1997 May;19(9):905-8.
21. Schleuning M, Buxbaum-Conradi H, Jager G, Kolb HJ.
Intravenous ribavirin for eradication of respiratory syncytial
virus (RSV) and adenovirus isolates from the respiratory
and/or gastrointestinal tract in recipients of allogeneic
hematopoietic stem cell transplants. Hematol J. 2004;5(2):
135-44.
22. Boeckh M, Berrey MM, Bowden RA, Crawford SW, Balsley J,
Corey L. Phase I Evaluation of the RSV-Specific Humanized
Monoclonal Antibody Palivizumab (MEDI-493) In
Hematopoietic Stem Cell Transplant Recipients. Journal of
Infectious Diseases. 2001; 184:350-54.
23. Small TN, Casson A, Malak SF, Boulad F, Kiehn TE, Stiles J, et
al. Respiratory syncytial virus infection following hematopoietic
stem cell transplantation. Bone Marrow Transplant. 2002
Feb;29(4):321-7.
24. DeVincenzo JP, Hirsch RL, Fuentes RJ, Top Jr FH. Respiratory
syncytial virus immune globulin treatment of lower respiratory
tract infection in pediatric patients undergoing bone mar-
London, United Kingdom, June 9-12, 2011
row transplantation - a compassionate use experience. Bone
marrow transplantation. 2000;25(2):161-5.
25. Choi SM, Boudreault AA, Xie H, Englund JA, Corey L,
Boeckh M. Differences in clinical outcomes following 2009
influenza A/H1N1 and seasonal influenza among hematopoietic
cell transplant recipients. Blood. 2011; In press.
26. Renaud C, Pergam SA, Polyak C, Jain R, Kuypers J, Englund
JA, et al. Early emergence of an H275Ymutation in a hemato -
poietic cell transplant recipient treated with intravenous
peramivir. Transplant Infectious Diseases. 2010; In press.
27. Boudreault A, Hu X, Wendy L, Janet E, Lawrence C, Michael
B. Impact of Corticosteroid Treatment and Antiviral Therapy
on Clinical Outcomes in Hematopoietic Cell Transplant
Patients Infected with Influenza Virus. Biology of Blood and
Marrow Transplantation. 2010; In press.
28. Peck AJ, Englund JA, Kuypers J, Guthrie KA, Corey L,
Morrow R, et al. Respiratory virus infection among
hematopoietic cell transplantation recipients: evidence for
asymptomatic parainfluenza virus infection. Blood. 2007
May 14;110:1681-8.
29. Erard V, Chien JW, Kim HW, Nichols WG, Flowers ME,
Martin PJ, et al. Airflow decline after myeloablative allogeneic
hematopoietic cell transplantation: the role of community
respiratory viruses. The Journal of infectious diseases. 2006
Jun 15;193(12):1619-25.
30. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M.
Parainfluenza virus infections after hematopoietic stem cell
transplantation: risk factors, response to antiviral therapy, and
effect on transplant Ootcome. Blood. 2001;In press.
31. Chakrabarti S, Collingham KE, Holder K, Oyaide S, Pillay D,
Milligan DW. Parainfluenza Virus Type 3 Infections in
Hematopoetic Stem Cell Transplant Recipients: Response to
Ribavirin Therapy. Clin Infect Dis. 2000;31(6):1516-8.
32. Englund J, Boeckh M, Kuypers J, Nichols WG, Hackman RC,
Morrow RA, et al. Fatal Human Metapneumovirus Infection
in Stem Cell Transplant Recipients. Annal of Internal
Medicine. 2006; 133:344-9.
33. Wyde PR, Chetty SN, Jewell AM, Boivin G, Piedra PA.
Comparison of the inhibition of human metapneumovirus
and respiratory syncytial virus by ribavirin and immune
serum globulin in vitro. Antiviral Res. 2003 Sep;60(1):51-9.
34. Gutman JA, Peck AJ, Kuypers J, Boeckh M. Rhinovirus as a
cause of fatal lower respiratory tract infection in adult stem
cell transplantation patients: a report of two cases. Bone marrow
transplantation. 2007;40:809-11.
35. Milano F, Campbell AP, Guthrie KA, Kuypers J, Englund JA,
Corey L, et al. Human rhinovirus and coronavirus detection
among allogeneic hematopoietic stem cell transplantation
recipients. Blood. Mar 11;115(10):2088-94.
36. Marty FM, Ljungman P, Papanicolaou GA, Winston DJ,
Chemaly RF, Strasfeld L, et al. Maribavir prophylaxis for prevention
of cytomegalovirus disease in recipients of allogeneic
stem-cell transplants: a phase 3, double-blind, placebo-controlled,
randomised trial. Lancet Infect Dis. 2011 Mar 15.
37. Kuritzkes DR, Parenti D, Ward DJ, Rachlis A, Wong RJ,
Mallon KP, et al. Filgrastim prevents severe neutropenia and
reduces infective morbidity in patients with advanced HIV
infection: results of a randomized, multicenter, controlled
trial. G-CSF 930101 Study Group. AIDS (London, England).
1998 Jan 1;12(1):65-74.
38. Rau R, Fitzhugh CD, Baird K, Cortez KJ, Li L, Fischer SH, et
al. Triad of severe abdominal pain, inappropriate antidiuretic
hormone secretion, and disseminated varicella-zoster virus
infection preceding cutaneous manifestations after
hematopoietic stem cell transplantation: utility of PCR for
early recognition and therapy. The Pediatric infectious disease
journal. 2008 Mar;27(3):265-8.
39. Erard V, Guthrie KA, Varley C, Heugel J, Wald A, Flowers ME,
et al. One-year acyclovir prophylaxis for preventing varicellazoster
virus disease after hematopoietic cell transplantation:
no evidence of rebound varicella-zoster virus disease after
drug discontinuation. Blood. 2007 Oct 15;110(8):3071-7.
40. Erard V, Wald A, Corey L, Leisenring WM, Boeckh M. Use of
long-term suppressive acyclovir after hematopoietic stem-cell
transplantation: impact on herpes simplex virus (HSV) disease
and drug-resistant HSV disease. The Journal of infectious diseases.
2007 Jul 15;196(2):266-70.
41. Safrin S, Berger TG, Gilson I, Wolfe PR, Wofsy CB, Mills J, et
al. Foscarnet therapy in five patients with AIDS and acyclovir-resistant
varicella-zoster virus infection. Annals of
internal medicine. 1991 Jul 1;115(1):19-21.
42. Zerr DM, Corey L, Kim HW, Huang ML, Nguy L, Boeckh M.
Clinical outcomes of human herpesvirus 6 reactivation after
hematopoietic stem cell transplantation. Clin Infect Dis. 2005
Hematology Education: the education programme for the annual congress of the European Hematology Association | 2011; 5(1) | 335 |